Menopause market is estimated to be US\$ 16.46 billion by 2030 with a CAGR of 4.50% during the forecast period

Menopause market accounted for US\$ 10.67 billion in 2020 and is estimated to be US\$ 16.46 billion by 2030 and is anticipated to register a CAGR of 4.50%. Menopause is the term used to describe the end of a woman's menstrual cycle. After a 12-month time without a menstrual period, it's diagnosed. Menopause can strike in your 40s or 50s, but in the United States, the average age is 51. Menopause is a normal part of the female reproductive system. However, menopause's physical and mental symptoms, like as hot flashes, can disrupt your sleep, diminish your energy, and damage your emotional health. From lifestyle changes to hormone medication, there are a variety of effective therapies available. Menopausal heat flashes are one of the menopause symptoms. They relate to the sensations of warmth that women experience as they approach menopause.

The report "Global Menopause market, By Treatment (Hormonal Treatment (Estrogen, Progesterone and Combination), Non-Hormonal Treatment (Anti-Depressants)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Stores), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030"

Key Highlights:

- Teva Pharmaceuticals announced the launch of a generic version of Estrace Cream in March 2018 to treat menopausal symptoms such vaginal and vulvar atrophy.
- HUM Nutrition, a prominent wellness brand, will debut FAN CLUBTM in 2021, an estrogen-free supplement that has been extensively studied to help women through perimenopause and menopause.
- In 2021, Bijuva (known as Bijuve in the UK) was launched by Theramex in Europe and the United Kingdom in 2021. It's the first and only body-identical hormone replacement medication (HRT) for oestrogen insufficiency symptoms in postmenopausal women with an intact uterus and at least 12 months since their last menstrual period, combining estradiol and progesterone in a single daily pill.

Analyst View:

The primary driving factors for the menopausal heat flashes market are the rising incidence of menopausal hot flashes, the increasing number of new pharmacological approvals for the treatment, and rising knowledge about menopause health. Hot flashes are a quick sensation of warmth that mainly affects the chest, neck, and face. Hot flashes produce flushing (redness of the skin) and profuse sweating. Menopause causes hot flashes, which occur when menstrual periods become erratic and eventually stop. Hot flashes are, in fact, the most prevalent symptom of menopausal transition (which includes stages such as premenopause, perimenopause, and post-menopause). Hot flashes can last from a few minutes to many hours, depending on the woman. Rapid heartbeat, flushed appearance with red, blotchy skin, perspiration, particularly on the upper body, a sudden feeling of warmth spreading through the upper body and face, and so on are some of the signs of a hot flash.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market insight/Insight/request-sample/4760

Key Market Insights from the report:

Global Menopause market accounted for US\$ 10.67 billion in 2020 and is estimated to be US\$ 16.46 billion by 2030 and is anticipated to register a CAGR of 4.50%. The Global Menopause market is segmented based on treatment, distribution channel and region.

- Based on Treatment, Global Menopause market is segmented into Hormonal Treatment (Estrogen, Progesterone and Combination), Non-Hormonal Treatment (Anti-Depressants).
- Based on Distribution Channel, Global Menopause market is segmented into Hospital Pharmacies,
 Retail Pharmacies and Online Stores.
- By Region, the Global Menopause market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Menopause market:

The menopausal hot flashes market is fragmented and competitive and consists of several major players. A large portion of the market share is taken up by small and mid-sized companies that produce generic treatment options. Some of the companies currently dominating the market are AbbVie Inc. (Allergan PLC), Bayer AG, Novartis AG, Pfizer Inc., Novo Nordisk Corporation, Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.